Healthcare Business Roundup: Boston Scientific Slams Johnson & Johnson

Spectrum Pharmaceuticals (NASDAQ:SPPI) announces positive results. Zevalin is improving outcomes of high-risk lymphomas according to a paper published by Cancer. SPPI shares were up premarket.

Columbia Labs (NASDAQ:CBRX) is down over 50% after trading was suspended following a negative vote on the company’s Prochieve drug candidate from the Food and Drug Administration. Partner, Watson Pharmaceuticals (NYSE:WPI) is little changed after falling slightly on Friday as well. Columbia Labs’ rival K-V (KV.A) is up again after a 9.3% gain on Friday.

Earnings Report: Bristol-Myers Squibb Co. Fourth Quarter Earnings Sneak Peek.

Boston Scientific (NYSE:BSX) announces a favorable ruling for a patent infringement case filed against BSX by Johnson & Johnson (NYSE:JNJ).

Alexa Pharmaceuticals (NASDAQ:ALXA) shares are hit hard after the Food and Drug Administration says it needs an additional three months to complete Adassuve’s, a schizophrenic and bipoloar disorder drug, application review.

Cel-Sci Corporation (AMEX:CVM) shares explode after phase III clinical trials for Multikine were launched in dozens of hospitals located in eight countries on three continents. Mulitkine is a cancer drug.

Don’t Miss: EA at Outperform Rating, Teradyne at Buy Rating, Biogen an Overweight.